SP
JSPR icon

Sequent Planning’s Jasper Therapeutics JSPR Stock Holding History

Sequent Planning’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1K Buy
14,900
+2,400
+19% +$3.33K ﹤0.01% 242
2025
Q4 		$22.9K Hold
12,500
– – 0.01% 226
2025
Q3 		$29.8K Buy
12,500
+2,000
+19% +$6.07K 0.01% 201
2025
Q2 		$58.3K Buy
+10,500
New +$51.7K 0.02% 162

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Sequent Planning's JSPR Position: Q1 2026 in Review

Sequent Planning increased its Jasper Therapeutics (JSPR) stake by 19% in Q1 2026, buying an estimated $3.33K and bringing the position to 14,900 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #242.

Sequent Planning first reported a position in JSPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $58.3K in Q2 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Sequent Planning held 14,900 shares of Jasper Therapeutics worth $13.1K as of Q1 2026.
  • Sequent Planning bought 2,400 Jasper Therapeutics shares in Q1 2026, an estimated $3.33K.
  • Jasper Therapeutics made up ﹤0.01% of Sequent Planning's portfolio in Q1 2026, its #242 holding.
  • Sequent Planning first reported a position in Jasper Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Sequent Planning's Jasper Therapeutics position peaked at $58.3K in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Sequent Planning's 13F filing for Q1 2026, filed 21 Apr 2026.